These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 25923677)

  • 1. Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.
    Andre JB; Nagpal S; Hippe DS; Ravanpay AC; Schmiedeskamp H; Bammer R; Palagallo GJ; Recht L; Zaharchuk G
    Neuroradiol J; 2015 Apr; 28(2):112-9. PubMed ID: 25923677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of recurrent high-grade gliomas treated with bevacizumab: A preliminary report of 3D pseudocontinuous artery spin labeling.
    Lyu Y; Liu S; You H; Hou B; Wang Y; Ma W; Feng F
    J Magn Reson Imaging; 2017 Aug; 46(2):565-573. PubMed ID: 27902863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
    Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
    Pichler J; Pachinger C; Pelz M; Kleiser R
    Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.
    Hamza MA; Mandel JJ; Conrad CA; Gilbert MR; Yung WK; Puduvalli VK; DeGroot JF
    J Neurooncol; 2014 Aug; 119(1):135-40. PubMed ID: 24803001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.
    Leu K; Enzmann DR; Woodworth DC; Harris RJ; Tran AN; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    Cancer Imaging; 2014 Nov; 14(1):31. PubMed ID: 25608485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
    Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma.
    Anderson MD; Hamza MA; Hess KR; Puduvalli VK
    Neuro Oncol; 2014 Jun; 16(6):823-8. PubMed ID: 24596117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.
    Levin VA; Mendelssohn ND; Chan J; Stovall MC; Peak SJ; Yee JL; Hui RL; Chen DM
    J Neurooncol; 2015 Mar; 122(1):145-50. PubMed ID: 25575937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.
    Goldlust SA; Cavaliere R; Newton HB; Hsu M; Deangelis LM; Batchelor TT; Gilbert MR; Lassman AB
    J Neurooncol; 2012 Apr; 107(2):407-11. PubMed ID: 22203237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.
    Chamberlain MC
    Expert Rev Neurother; 2012 Aug; 12(8):929-36. PubMed ID: 23002937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
    Netto JP; Schwartz D; Varallyay C; Fu R; Hamilton B; Neuwelt EA
    Fluids Barriers CNS; 2016 Dec; 13(1):23. PubMed ID: 27998280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional and voxel-wise comparisons of blood flow measurements between dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) and arterial spin labeling (ASL) in brain tumors.
    White CM; Pope WB; Zaw T; Qiao J; Naeini KM; Lai A; Nghiemphu PL; Wang JJ; Cloughesy TF; Ellingson BM
    J Neuroimaging; 2014; 24(1):23-30. PubMed ID: 22672084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy.
    Stadlbauer A; Pichler P; Karl M; Brandner S; Lerch C; Renner B; Heinz G
    Eur J Radiol; 2015 Jun; 84(6):1128-36. PubMed ID: 25795194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
    Fellah S; Girard N; Chinot O; Cozzone PJ; Callot V
    J Clin Oncol; 2011 Apr; 29(11):e308-11. PubMed ID: 21263101
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic value of relative cerebral blood volume in patients with recurrent glioblastoma multiforme treated with bevacizumab.
    Stecco A; Amatuzzo P; Sponghini AP; Platini F; Quagliozzi M; Buemi F; Guenzi E; Carriero A
    J Neurosurg Sci; 2019 Aug; 63(4):394-401. PubMed ID: 27603407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
    Pope WB; Xia Q; Paton VE; Das A; Hambleton J; Kim HJ; Huo J; Brown MS; Goldin J; Cloughesy T
    Neurology; 2011 Feb; 76(5):432-7. PubMed ID: 21282590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.